Abstract:From the 33,000 men in the U.S. who die from prostate cancer each year, the majority of these patients exhibit metastatic disease with bone being the most common site of metastasis. Prostate cancer bone metastases are commonly blastic, exhibiting new growth of unhealthy sclerotic bone, which can cause painful skeletal related events. Patient's current care entails androgen deprivation therapy, anti-resorptive agents, radiation, and chemotherapy to help control the spread of the cancer but little intervention is available to treat blastic bone disease. The transforming growth factor beta (TGFβ) and bone morphogenetic protein (BMP) pathways are known to regulate bone growth and resorption of destructive lytic bone lesions, yet the role of TGFβ/BMP signaling in prostate cancer blastic vs lytic bone lesions are not fully understood. We hypothesized that to target the BMP/TGFβ pathway, a useful biomarker of bone lytic or blastic pathology would have superior response. We show distinct BMP vs. TGFβ signaling in clinical samples of human prostate cancer bone metastases with either lytic or blastic pathologies. BMPs exhibit distinct effects on bone homeostasis, so to examine the effect of BMP inhibition on healthy bone, we treated mice with the BMP receptor small molecule antagonist DMH1 and saw a modest temporary improvement in bone health, with increased trabecular bone. We next sought to use the BMP inhibitor DMH1 to treat bone metastasis engraftment seeded by a caudal artery injection of the lytic human prostate cell line PC3 in immunodeficient mice. The colonization by PC3 cells to the bone were restricted with DMH1 treatment and bone health was importantly preserved. We next proceeded to test BMP inhibition in an injury model of established bone metastasis via intratibial injection of the MYC-CaP mouse prostate cell line into FVBN syngeneic mice. DMH1 treated mice had a modest decrease in trabecular bone and reduced lymphocytes in circulation without affecting tumor growth. Taken together we show unique responses to BMP inhibition in metastatic prostate cancer in the bone. These studies suggest that profiling bone lesions in metastatic prostate cancer can help identify therapeutic targets that not only treat the metastatic tumor but also address the need to better treat the distinct tumor induced bone disease.

PTHrP Inhibits BMP-6 Expression Through the PKA Signaling Pathway in Breast Cancer Cells

Bone Morphogenetic Protein 9 Regulates the Cross-Talk Between Breast Cancer Cells and Bone Marrow Mesenchymal Stem Cells

BMP9 Regulates Cross-Talk Between Breast Cancer Cells and Bone Marrow-Derived Mesenchymal Stem Cells.

Biological Roles of Human Bone Morphogenetic Protein 9 in the Bone Microenvironment of Human Breast Cancer MDA-MB-231 Cells.

BMP9 Inhibits Proliferation and Metastasis of HER2-positive SK-BR-3 Breast Cancer Cells Through ERK1/2 and PI3K/AKT Pathways.

PTHrP expression in human MDA-MB-231 breast cancer cells is critical for tumor growth and survival and osteoblast inhibition

Increased Expression of Preprotachykinin-I and Neurokinin Receptors in Human Breast Cancer Cells: Implications for Bone Marrow Metastasis.

PTHrP is a Novel Mediator for TGF-β-induced Apoptosis.

Phosphatidylethanolamine-binding protein 4 is associated with breast cancer metastasis through Src-mediated Akt tyrosine phosphorylation

NKX2-8/PTHrP Axis-Mediated Osteoclastogenesis and Bone Metastasis in Breast Cancer

PTHrP intracrine actions divergently influence breast cancer growth through p27 and LIFR

Bone Morphogenetic Proteins, Breast Cancer, and Bone Metastases: Striking the Right Balance

DLC1-dependent parathyroid hormone-like hormone inhibition suppresses breast cancer bone metastasis.

Parathyroid hormone related-protein (PTHrP) in tissues with poor prognosis in prostate cancer patients

Upregulated bone morphogenetic protein 8A (BMP8A) in triple negative breast cancer (TNBC) and its involvement in the bone metastasis

CircMMP2(6,7) cooperates with β-catenin and PRMT5 to disrupt bone homeostasis and promote breast cancer bone metastasis

Aberrant Expression of Bone Morphogenetic Proteins in the Disease Progression and Metastasis of Breast Cancer

Targeting the BMP Pathway in Prostate Cancer Induced Bone Disease

Amphiregulin-Egfr Signaling Mediates the Migration of Bone Marrow Mesenchymal Progenitors Toward Pth-Stimulated Osteoblasts and Osteocytes

Targeted overexpression of BSP in osteoclasts promotes bone metastasis of breast cancer cells

Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression.